Whitehawk Therapeutics, Inc. WHWK
3.05 USD -0.19 (-5.86%)
Nov 12, 2026, 2:07 PM EST
3.00 Day range 3.21
1.97 52-week range 5.50
- YTD
- +26.03%
- 1 year
- +36.77%
- Market cap
- 179.98M
- EPS (ttm)
- -1.10
- YTD return
- +26.03%
- 1-year return
- +36.77%
- Volume
- 147.96K
- Avg volume
- 340.71K
- Open
- 3.21
- Previous close
- 3.24
- Day's range
- 3.00 – 3.21
- 52-week range
- 1.97 – 5.50
No chart data for this range yet.
Financials — quick view
WHWK Revenue — quarterly 0
WHWK Net income — quarterly -21.21M
WHWK EPS — quarterly -0.23
News
Whitehawk Therapeutics Q3 EPS $(0.23) Misses $(0.21) Estimate 
Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights 
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16 
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9 
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC 
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate - Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9
- Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock
Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO 
12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on WHWK — it syncs with the Stock Master app.